1.59

6.47% -0.11

Pre-market: 1.66 0.07 +4.40%

Palisade Bio Inc (PALI)

Overview News Price History Financials Discussions Forecast Stock Split

Palisade Bio Inc stock is traded at $1.59, with a volume of 6.87M. It is down -6.47% in the last 24 hours and down -22.06% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Previous Close:

$1.70

Open:

$1.68

24h Volume:

6.87M

Relative Volume:

2.45

Market Cap:

$277.09M

Revenue:

$250.00K

Net Income/Loss:

$-24.15M

P/E Ratio:

-1.4921

EPS:

-1.0656

Net Cash Flow:

$-12.40M

1W Performance:

-22.82%

1M Performance:

-22.06%

6M Performance:

-19.29%

1Y Performance:

+165.89%

1-Day Range:

$1.585

$1.72

1-Week Range:

$1.585

$2.11

52-Week Range:

$0.58

$2.855

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1065)

Industry

Biotechnology (594)

Phone

(858) 704-4900

Address

7750 EL CAMINO REAL, SUITE 5200, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

PALI's Discussions on Twitter

Compare PALI vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PALI Palisade Bio Inc	1.59	359.00M	250.00K	-24.15M	-12.40M	-1.0656
VRTX Vertex Pharmaceuticals Inc	508.34	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	784.85	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.32	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	154.04	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	190.95	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Palisade Bio Inc Stock (PALI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-26-26	Initiated	H.C. Wainwright	Buy
Feb-25-26	Initiated	Stifel	Buy
Jan-09-26	Initiated	B. Riley Securities	Buy
Dec-29-25	Initiated	Piper Sandler	Overweight

Palisade Bio Inc Stock (PALI) Latest News

Sep 09, 2026

Here's Why We're Not Too Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn Situation - simplywall.st

Sep 09, 2026

Sep 08, 2026

Palisade Bio (PALI) Advances 5.26% as Shares Test Key Resistance at $2.31Regression Channel - siam.in

Sep 08, 2026

Sep 03, 2026

Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewswire

Sep 03, 2026

Three September healthcare conferences will include Palisade Bio management - Stock Titan

Sep 03, 2026

Aug 21, 2026

Palisade Bio (PALI) CEO reallocates 176K shares in gifts - Stock Titan

Aug 21, 2026

Aug 18, 2026

Palisade Bio Q3 EPS Decreased by Brookline Capital Markets - MarketBeat

Aug 18, 2026

Aug 17, 2026

Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView

Aug 17, 2026

FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat

Aug 17, 2026

Aug 15, 2026

Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et

Aug 15, 2026

Aug 14, 2026

Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan

Aug 14, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 14, 2026

Aug 13, 2026

Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan

Aug 13, 2026

HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat

Aug 13, 2026

Aug 12, 2026

Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail

Aug 12, 2026

Aug 11, 2026

Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 11, 2026

H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 11, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - The Manila Times

Aug 11, 2026

Aug 10, 2026

Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia

Aug 10, 2026

Palisade Bio clears FDA for Phase 2 UC trial - scanx.trade

Aug 10, 2026

Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade

Aug 10, 2026

Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat

Aug 10, 2026

Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative

Aug 10, 2026

Palisade Bio Q2 net loss widens on higher R&D costs - TradingView

Aug 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire

Aug 10, 2026

PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - TradingView

Aug 10, 2026

Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 10, 2026

Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI - MarketBeat

Aug 10, 2026

PALI Q2 2026 Earnings: EPS Surprise of 6.19% Highlights Controlled SpendingEarnings Deceleration Risk - vinanet.vn

Aug 10, 2026

Aug 09, 2026